JT 15
Alternative Names: JT-15Latest Information Update: 16 Feb 2024
At a glance
- Originator Canget BioTekpharma
- Class Antineoplastics; Small molecules
- Mechanism of Action BIRC5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Colorectal cancer; Lung cancer; Ovarian cancer
Most Recent Events
- 24 Jan 2024 JT 15 is available for licensing as of 24 Jan 2024. http://www.canget-biotek.com/business%20models.php (Canget BioTekpharma pipeline, January 2024)
- 24 Jan 2024 Preclinical trials in Colorectal cancer in USA (PO) prior to January 2024 (Canget BioTekpharma pipeline, January 2024)
- 24 Jan 2024 Preclinical trials in Lung cancer in USA (PO) prior to January 2024 (Canget BioTekpharma pipeline, January 2024)